Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach

Ejemplares similares

• Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety
  por: Cheng Jiang, et al.
  Publicado: (2024)
• Predictors of gentamicin therapy failure in neonates with sepsis
  por: Bonifasius Siyuka Singu, et al.
  Publicado: (2024)
• Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors
  por: Jennifer H. Martin, et al.
  Publicado: (2024)
• Development of a pharmaceutical science systematic review process using a semi‐automated machine learning tool: Intravenous drug compatibility in the neonatal intensive care setting
  por: D. Thisuri N. De Silva, et al.
  Publicado: (2024)
• An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction
  por: Ryutaro Iwama, et al.
  Publicado: (2024)